Literature DB >> 31138592

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation.

Miney Paquette1,2, Daniel M Witt3, Anne Holbrook4,5, Jane Skov6, Jack Ansell7, Holger J Schünemann1,5, Wojtek Wiercioch1, Robby Nieuwlaat1.   

Abstract

Oral anticoagulants (OACs) are indicated for treatment and prevention of thromboembolic diseases. Supplemental patient education (education) has been proposed to improve outcomes, and this systematic review assesses the effect of education on mortality, thromboembolic events (TEEs) including venous thromboembolism (VTE), and bleeding in patients taking OACs. Randomized controlled trials were included, and 2 authors independently screened articles and assessed risk of bias. In 9 trials (controls, n = 720; intervention group patients, n = 646), 4 assessed critical outcomes of mortality, TEEs (VTE, stroke, and systemic embolism), and bleeding to estimate absolute risk ratios. When comparing education with usual care, in 1000 patients, there may be 12 fewer deaths (95% confidence interval [CI], 19 fewer to 154 more) and 16 fewer bleeding events (95% CI, 34 fewer to 135 more), but this evidence is uncertain; the evidence also suggests 6 fewer VTEs (95% CI, 10 fewer to 16 more) and 8 fewer TEEs (95% CI, 16 fewer to 18 more). The mean difference in time in therapeutic range may be 2.4% higher in the education group compared with usual care (95% CI, 2.79% lower to 7.58% higher). We also found very low certainty of evidence for a large increase in knowledge scores (standardized mean difference, 0.84 standard deviation units higher; 95% CI, 0.51-1.16). Overall, the certainty of evidence was low to very low because of serious risk of bias and serious imprecision. Additional sufficiently powered trials or different approaches to education are required to better assess supplemental education effects on outcomes in patients taking OACs.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31138592      PMCID: PMC6538874          DOI: 10.1182/bloodadvances.2019000067

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  26 in total

1.  The hazards of interrupting anticoagulation therapy in atrial fibrillation.

Authors:  Stefan H Hohnloser; John W Eikelboom
Journal:  Eur Heart J       Date:  2012-02-24       Impact factor: 29.983

2.  Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial.

Authors:  Silvy Laporte; Sara Quenet; Andréa Buchmüller-Cordier; Jacqueline Reynaud; Brigitte Tardy-Poncet; Christine Thirion; Hervé Decousus; Patrick Mismetti
Journal:  Thromb Haemost       Date:  2003-03       Impact factor: 5.249

3.  Evaluation of the use of programmed instruction for patients maintained on Warfarin therapy.

Authors:  C M Clark; E W Bayley
Journal:  Am J Public Health       Date:  1972-08       Impact factor: 9.308

Review 4.  Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis.

Authors:  P Y H Wong; S Schulman; S Woodworth; A Holbrook
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

Review 5.  Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.

Authors:  Danielle E Clarkesmith; Helen M Pattison; Phyo H Khaing; Deirdre A Lane
Journal:  Cochrane Database Syst Rev       Date:  2017-04-05

6.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

7.  EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study.

Authors:  Gilles Pernod; José Labarère; Jacqueline Yver; Bernadette Satger; Benoit Allenet; Touffek Berremili; Michèle Fontaine; Guy Franco; Jean Luc Bosson
Journal:  J Gen Intern Med       Date:  2008-06-20       Impact factor: 5.128

8.  Cardiovascular risk factors and venous thromboembolism: a meta-analysis.

Authors:  Walter Ageno; Cecilia Becattini; Timothy Brighton; Rita Selby; Pieter W Kamphuisen
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Open Med       Date:  2009-07-21

10.  Estimating the mean and variance from the median, range, and the size of a sample.

Authors:  Stela Pudar Hozo; Benjamin Djulbegovic; Iztok Hozo
Journal:  BMC Med Res Methodol       Date:  2005-04-20       Impact factor: 4.615

View more
  2 in total

1.  Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial.

Authors:  Lamis R Karaoui; Elsy Ramia; Hanine Mansour; Nisrine Haddad; Nibal Chamoun
Journal:  BMC Health Serv Res       Date:  2021-02-16       Impact factor: 2.655

2.  Assessment of Knowledge Regarding Risks and Benefits of the Use of Non-Vitamin K Antagonist Oral Anticoagulants.

Authors:  Jose Raul Valery; Ahmad Marar; George Pujalte; Cynthia Ward; Yousif M Abdelmoneim; Patrick J Fitzgerald; Edson Mwakyanjala; Dana M Harris; Loren Murray; Michael G Heckman; Launia J White; Fernando Stancampiano
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.